Q-omics provides the consensus-scored RPL18AP8 profile across patient tissues and cancer cell-line models. RPL18AP8 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, RPL18AP8 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, RPL18AP8 RNA expression shows 5,583 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BLCA, KIRC, and STAD as cancer lineages where RPL18AP8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL18AP8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL18AP8 survival associations across molecular data types. RPL18AP8 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL18AP8 RNA expression–survival associations across cancer types. High RPL18AP8 expression shows unfavorable associations in BLCA, LIHC, LUAD and ACC, but favorable associations in READ and UCS. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for RPL18AP8 RNA expression.
This table summarizes RPL18AP8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL18AP8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL18AP8 shows lower tumor expression in THCA and higher tumor expression in KIRC, COAD, LUAD, LIHC and LUSC. The KIRC box plot shows higher RPL18AP8 RNA expression in tumor versus normal tissue (log2 FC = +0.047, t-test p < 0.001).
This table shows molecular features associated with RPL18AP8 in patient tissues and cancer cell lines. In patient samples, RPL18AP8 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
